"Dasatinib" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pyrimidine and thiazole derived ANTINEOPLASTIC AGENT and PROTEIN KINASE INHIBITOR of BCR-ABL KINASE. It is used in the treatment of patients with CHRONIC MYELOID LEUKEMIA who are resistant or intolerant to IMATINIB.
| Descriptor ID |
D000069439
|
| MeSH Number(s) |
D02.886.675.184 D03.383.129.708.198 D03.383.742.148
|
| Concept/Terms |
Dasatinib- Dasatinib
- N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
BMS 354825- BMS 354825
- 354825, BMS
- BMS354825
- BMS-354825
|
Below are MeSH descriptors whose meaning is more general than "Dasatinib".
Below are MeSH descriptors whose meaning is more specific than "Dasatinib".
This graph shows the total number of publications written about "Dasatinib" by people in this website by year, and whether "Dasatinib" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 2 | 2 |
| 2012 | 0 | 1 | 1 |
| 2014 | 0 | 2 | 2 |
| 2015 | 2 | 0 | 2 |
| 2016 | 1 | 1 | 2 |
| 2017 | 1 | 0 | 1 |
| 2022 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dasatinib" by people in Profiles.
-
Senolytic treatment reduces cell senescence and necroptosis in Sod1 knockout mice that is associated with reduced inflammation and hepatocellular carcinoma. Aging Cell. 2022 Aug; 21(8):e13676.
-
Induction of Cellular Senescence in Rat Vaginal Fibroblasts and Treatment With Senolytics: An in Vitro Model for the Study of Pelvic Organ Prolapse. Female Pelvic Med Reconstr Surg. 2022 05 01; 28(5):341-345.
-
Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL. Blood Adv. 2021 11 23; 5(22):4691-4700.
-
Dasatinib Reinitiation After Poststroke Thrombolysis Associated with Symptomatic Intracerebral Hemorrhage. World Neurosurg. 2019 05; 125:383-386.
-
Pretreatment With Rifampicin and Tyrosine Kinase Inhibitor Dasatinib Potentiates the Inhibitory Effects Toward OATP1B1- and OATP1B3-Mediated Transport. J Pharm Sci. 2017 08; 106(8):2123-2135.
-
Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab. Clin Cancer Res. 2017 Jun 15; 23(12):2972-2980.
-
Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. Aging Cell. 2016 06; 15(3):428-35.
-
Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. Ann Oncol. 2016 Feb; 27(2):318-23.
-
The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015 Aug; 14(4):644-58.
-
Inhibition of calcineurin combined with dasatinib has direct and indirect anti-leukemia effects against BCR-ABL1(+) leukemia. Am J Hematol. 2014 Sep; 89(9):896-903.